IMP-731 is under clinical development by GSK and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect IMP-731’s likelihood of approval (LoA) and phase transition for Autoimmune Disorders took place on 10 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 10 Jun 2021 increased IMP-731’s LoA and PTSR for Plaque Psoriasis (Psoriasis Vulgaris).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IMP-731 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
IMP-731 is under development for the treatment of plaque psoriasis, ulcerative colitis and other autoimmune disorders. IMP-731 is a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
Quick View IMP-731 LOA Data
|Highest Development Stage|